Related Experiment Video

Updated: Jun 12, 2026

Creation of Patient-Specific Silicone Cardiac Models with Applications in Pre-surgical Plans and Hands-on Training
09:15

Creation of Patient-Specific Silicone Cardiac Models with Applications in Pre-surgical Plans and Hands-on Training

Published on: February 10, 2022

Pediatric cardiac devices--an FDA pediatrician's perspective of the challenges and potential solutions

Francesca Dolcimascolo1

  • 1FDA, Silver Spring, MD, USA. francesca.dolcimascolo@fda.hhs.gov

Journal of Cardiovascular Translational Research
|June 19, 2010
PubMed

Insights

Advancing pediatric medical devices presents significant challenges for the Food and Drug Administration and healthcare providers. This work outlines these hurdles and proposes potential solutions for improved child healthcare technology.

Area of Science:

  • Biomedical Engineering
  • Regulatory Science
  • Pediatric Healthcare

Background:

  • Pediatric medical devices require specialized considerations due to unique patient populations.
  • Current regulatory pathways and device development face significant obstacles in pediatric applications.

Purpose of the Study:

  • To identify and delineate the key challenges in advancing pediatric medical device development.
  • To propose actionable solutions and strategies to overcome these identified challenges.

Main Methods:

  • Literature review of existing pediatric medical device challenges.
  • Analysis of regulatory frameworks and industry best practices.
  • Synthesis of expert opinions and case studies.

Main Results:

  • Key challenges include small market size, unique pediatric physiology, and complex regulatory requirements.
  • Proposed solutions involve enhanced regulatory pathways, innovative funding models, and collaborative development efforts.

Conclusions:

  • Addressing the unique challenges in pediatric medical device development is crucial for improving child health outcomes.
  • A multi-faceted approach involving regulatory bodies, industry, and healthcare professionals is essential for progress.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...